Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 58

1.

Hypertension update, JNC8 and beyond.

Shrout T, Rudy DW, Piascik MT.

Curr Opin Pharmacol. 2017 Apr;33:41-46. doi: 10.1016/j.coph.2017.03.004. Epub 2017 May 16. Review.

PMID:
28525818
2.

α₁A-adrenergic receptors regulate cardiac hypertrophy in vivo through interleukin-6 secretion.

Papay RS, Shi T, Piascik MT, Naga Prasad SV, Perez DM.

Mol Pharmacol. 2013 May;83(5):939-48. doi: 10.1124/mol.112.084483. Epub 2013 Feb 12.

3.

The alpha1D-adrenergic receptor induces vascular smooth muscle apoptosis via a p53-dependent mechanism.

García-Cazarín ML, Smith JL, Clair DK, Piascik MT.

Mol Pharmacol. 2008 Oct;74(4):1000-7. doi: 10.1124/mol.108.047993. Epub 2008 Jul 15.

PMID:
18628404
4.

The alpha1D-adrenergic receptor is expressed intracellularly and coupled to increases in intracellular calcium and reactive oxygen species in human aortic smooth muscle cells.

García-Cazarín ML, Smith JL, Olszewski KA, McCune DF, Simmerman LA, Hadley RW, Kraner SD, Piascik MT.

J Mol Signal. 2008 Feb 27;3:6. doi: 10.1186/1750-2187-3-6.

5.

The protective roles of nitric oxide and superoxide dismutase in adriamycin-induced cardiotoxicity.

Cole MP, Chaiswing L, Oberley TD, Edelmann SE, Piascik MT, Lin SM, Kiningham KK, St Clair DK.

Cardiovasc Res. 2006 Jan;69(1):186-97. Epub 2005 Sep 12.

PMID:
16157314
6.

The alpha(1B)-adrenergic receptor decreases the inotropic response in the mouse Langendorff heart model.

Ross SA, Rorabaugh BR, Chalothorn D, Yun J, Gonzalez-Cabrera PJ, McCune DF, Piascik MT, Perez DM.

Cardiovasc Res. 2003 Dec 1;60(3):598-607.

PMID:
14659805
7.

Differential cardiovascular regulatory activities of the alpha 1B- and alpha 1D-adrenoceptor subtypes.

Chalothorn D, McCune DF, Edelmann SE, Tobita K, Keller BB, Lasley RD, Perez DM, Tanoue A, Tsujimoto G, Post GR, Piascik MT.

J Pharmacol Exp Ther. 2003 Jun;305(3):1045-53. Epub 2003 Mar 20.

PMID:
12649302
8.

Gene expression profiling of alpha(1b)-adrenergic receptor-induced cardiac hypertrophy by oligonucleotide arrays.

Yun J, Zuscik MJ, Gonzalez-Cabrera P, McCune DF, Ross SA, Gaivin R, Piascik MT, Perez DM.

Cardiovasc Res. 2003 Feb;57(2):443-55.

PMID:
12566117
9.

Differences in the cellular localization and agonist-mediated internalization properties of the alpha(1)-adrenoceptor subtypes.

Chalothorn D, McCune DF, Edelmann SE, García-Cazarín ML, Tsujimoto G, Piascik MT.

Mol Pharmacol. 2002 May;61(5):1008-16.

PMID:
11961118
11.

Alpha1-adrenergic receptors: new insights and directions.

Piascik MT, Perez DM.

J Pharmacol Exp Ther. 2001 Aug;298(2):403-10. Review.

PMID:
11454900
12.

Hypotension, autonomic failure, and cardiac hypertrophy in transgenic mice overexpressing the alpha 1B-adrenergic receptor.

Zuscik MJ, Chalothorn D, Hellard D, Deighan C, McGee A, Daly CJ, Waugh DJ, Ross SA, Gaivin RJ, Morehead AJ, Thomas JD, Plow EF, McGrath JC, Piascik MT, Perez DM.

J Biol Chem. 2001 Apr 27;276(17):13738-43. Epub 2001 Feb 1.

13.

Regulation of the cellular localization and signaling properties of the alpha(1B)- and alpha(1D)-adrenoceptors by agonists and inverse agonists.

McCune DF, Edelmann SE, Olges JR, Post GR, Waldrop BA, Waugh DJ, Perez DM, Piascik MT.

Mol Pharmacol. 2000 Apr;57(4):659-66.

PMID:
10727510
14.

Cloning, cell-type specificity, and regulatory function of the mouse alpha(1B)-adrenergic receptor promoter.

Zuscik MJ, Piascik MT, Perez DM.

Mol Pharmacol. 1999 Dec;56(6):1288-97.

PMID:
10570057
15.

Expression of multiple alpha1-adrenoceptors on vascular smooth muscle: correlation with the regulation of contraction.

Hrometz SL, Edelmann SE, McCune DF, Olges JR, Hadley RW, Perez DM, Piascik MT.

J Pharmacol Exp Ther. 1999 Jul;290(1):452-63.

PMID:
10381812
18.

Central hypotensive effects of the alpha2a-adrenergic receptor subtype.

MacMillan LB, Hein L, Smith MS, Piascik MT, Limbird LE.

Science. 1996 Aug 9;273(5276):801-3.

PMID:
8670421
19.

Recent advances in the molecular pharmacology of the alpha 1-adrenergic receptors.

Guarino RD, Perez DM, Piascik MT.

Cell Signal. 1996 Aug;8(5):323-33. Review.

PMID:
8911680
20.

alpha 1-adrenergic receptor subtypes. Molecular structure, function, and signaling.

Graham RM, Perez DM, Hwa J, Piascik MT.

Circ Res. 1996 May;78(5):737-49. Review. No abstract available.

PMID:
8620593
21.

Alpha-adrenoceptors and vascular regulation: molecular, pharmacologic and clinical correlates.

Piascik MT, Soltis EE, Piascik MM, Macmillan LB.

Pharmacol Ther. 1996;72(3):215-41. Review.

PMID:
9364576
22.

The specific contribution of the novel alpha-1D adrenoceptor to the contraction of vascular smooth muscle.

Piascik MT, Guarino RD, Smith MS, Soltis EE, Saussy DL Jr, Perez DM.

J Pharmacol Exp Ther. 1995 Dec;275(3):1583-9.

PMID:
8531132
23.
24.
25.

The regulation of regional hemodynamics by alpha-1 adrenoceptor subtypes in the conscious rat.

Piascik MT, Smith MS, Barron KW, Soltis EE.

J Pharmacol Exp Ther. 1993 Dec;267(3):1250-5.

PMID:
8263787
26.

Effect of chlorethylclonidine on arterial blood pressure and heart rate in the conscious rat.

Piascik MT, Sparks MS, Pruitt TA.

J Pharmacol Exp Ther. 1992 Sep;262(3):901-6.

PMID:
1356153
27.
28.

Evidence for a complex interaction between the subtypes of the alpha 1-adrenoceptor.

Piascik MT, Sparks MS, Pruitt TA, Soltis EE.

Eur J Pharmacol. 1991 Jul 9;199(3):279-89.

PMID:
1680715
29.

Interaction of imidazolines with alkylation-sensitive and -resistant alpha-1 adrenoceptor subtypes.

Piascik MT, Sparks MS, Pruitt TA.

J Pharmacol Exp Ther. 1991 Jul 1;258(1):158-65.

PMID:
1677036
30.

Alpha 1-adrenoceptor subtypes and the regulation of peripheral hemodynamics in the conscious rat.

Piascik MT, Kusiak JW, Barron KW.

Eur J Pharmacol. 1990 Sep 21;186(2-3):273-8.

PMID:
1981186
31.

Agonist interaction with alkylation-sensitive and -resistant alpha-1 adrenoceptor subtypes.

Piascik MT, Butler BT, Pruitt TA, Kusiak JW.

J Pharmacol Exp Ther. 1990 Sep;254(3):982-91.

PMID:
1975627
32.

The role of alpha 1-adrenoceptor subtypes in the regulation of arterial blood pressure.

Piascik MT, Butler BT, Pruitt TA.

Eur J Pharmacol. 1990 May 16;180(2-3):381-6.

PMID:
2163870
33.

Stereoselective and nonstereoselective inhibition exhibited by the enantiomers of verapamil.

Piascik MT, Collins R, Butler BT.

Can J Physiol Pharmacol. 1990 Mar;68(3):439-46.

PMID:
2157545
34.

Effect of an alkylating analog of prazosin on alpha-1 adrenoceptor subtypes and arterial blood pressure.

Piascik MT, Butler BT, Kusiak JW, Pitha J, Holtman JR Jr.

J Pharmacol Exp Ther. 1989 Dec;251(3):878-83.

PMID:
2574745
35.

Interaction of a chemically reactive prazosin analog with alpha-1 adrenoceptors of rat tissues.

Kusiak JW, Pitha J, Piascik MT.

J Pharmacol Exp Ther. 1989 Apr;249(1):70-7.

PMID:
2565396
37.

Alkylation of alpha-1 receptors with a chemically reactive analog of prazosin reveals low affinity sites for norepinephrine in rabbit aorta.

Piascik MT, Kusiak JW, Pitha J, Butler BT, Le HT, Babich M.

J Pharmacol Exp Ther. 1988 Sep;246(3):1001-11.

PMID:
2843622
38.
39.

Calmodulin activation and calcium regulation of parotid gland adenylate cyclase.

Piascik MT, Babich M, Jacobson KL, Watson EL.

Am J Physiol. 1986 Apr;250(4 Pt 1):C642-5.

PMID:
3083690
40.
41.

Aspects of the clinical pharmacology of nifedipine, a dihydropyridine calcium-entry antagonist.

Hamann SR, Piascik MT, McAllister RG Jr.

Biopharm Drug Dispos. 1986 Jan-Feb;7(1):1-10. Review.

PMID:
3513860
42.

A method for enriching the cadmium content of cigarette smoke and effect of exposure to this smoke on coronary vascular reactivity in the rat.

Piascik MT, Champney RB, Kasarskis EJ, Forrester T.

Toxicol Appl Pharmacol. 1985 Dec;81(3 Pt 1):525-32.

PMID:
4082199
43.

Ca2+-dependent inhibition of smooth muscle adenylate cyclase activity.

Piascik MT, Addison B, Babich M.

Arch Biochem Biophys. 1985 Aug 15;241(1):28-35.

PMID:
4040733
44.
45.
46.

First degree A-V block in patients on lithium carbonate.

Martin CA, Piascik MT.

Can J Psychiatry. 1985 Mar;30(2):114-6.

PMID:
3922608
47.

Effects of verapamil on the arrhythmogenic action of acetylstrophanthidin.

Babich M, Hamann SR, McAllister RG Jr, Pratap Reddy C, Piascik MT.

Pharmacology. 1984;29(4):224-32.

PMID:
6494234
48.

Calmodulin stimulation and calcium regulation of smooth muscle adenylate cyclase activity.

Piascik MT, Babich M, Rush ME.

J Biol Chem. 1983 Sep 25;258(18):10913-8.

49.

Aspects of the clinical pharmacology of verapamil, a calcium-entry antagonist.

McAllister RG Jr, Hamann SR, Piascik MT.

Biopharm Drug Dispos. 1983 Jul-Sep;4(3):203-11. Review. No abstract available.

PMID:
6354294
50.

Ca2+-dependent regulation of rat caudate nucleus adenylate cyclase and effects on the response to dopamine.

Piascik MT, Piascik MF, Hitzemann RJ, Potter JD.

Mol Pharmacol. 1981 Sep;20(2):319-25. No abstract available.

PMID:
7300817

Supplemental Content

Loading ...
Support Center